How These Biotech Stocks are Faring? -- FibroGen, Bellicum Pharma, Intercept Pharma, and Cellect Biotechnology

Monday, April 17, 2017 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, April 17, 2017 /PRNewswire/ --

On Thursday, April 13, 2017, the NASDAQ Composite,

the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Nine out of nine sectors ended Thursday's trading session in bearish territories. Taking into consideration Thursday's market sentiment, assessed
the following Biotechnology equities this morning: FibroGen Inc. (NASDAQ: FGEN), Bellicum Pharmaceuticals Inc. (NASDAQ: BLCM), Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), and Cellect Biotechnology Ltd (NASDAQ: APOP). Download the free research reports on these stocks today:


San Francisco, California headquartered FibroGen Inc.'s stock advanced 2.85%, to close the day at $25.25. The stock recorded a trading volume of 450,600 shares. FibroGen's shares have gained 2.23% in the previous three months and 24.02% in the past one year. The Company's shares are trading 2.26% and 19.63% above its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the US, have a Relative Strength Index (RSI) of 52.06. See our free and comprehensive research report on FGEN at:

Bellicum Pharma  

On Thursday, shares in Houston, Texas headquartered Bellicum Pharmaceuticals Inc. ended the session 3.40% higher at $13.39 with a total volume of 528,997 shares traded. Bellicum Pharma's shares have gained 20.85% in the past one year. The stock is trading 3.49% above its 50-day moving average. Moreover, shares of the Company, which focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the US and internationally, has an RSI of 53.95. BLCM free research report PDF is just a click away at:

Intercept Pharma  

On Thursday, shares in New York headquartered Intercept Pharmaceuticals Inc. recorded a trading volume of 496,406 shares, which was above their three months average volume of 451,940 shares. The stock ended the day 1.47% higher at $107.33. Intercept Pharma's stock is trading below its 50-day and 200-day moving averages by 9.71% and 17.91%, respectively. Furthermore, shares of Intercept Pharma, which focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases, have an RSI of 31.82. Sign up for your complimentary report on ICPT at:

Cellect Biotechnology  

Kfar Saba, Israel-based Cellect Biotechnology Ltd's stock finished Thursday's session 0.24% lower at $8.25 with a total volume of 24,754 shares traded. Over the last one month and the previous three months, Cellect Biotechnology's shares have gained 29.72% and 35.02%, respectively. The Company's shares are trading above its 50-day and 200-day moving averages by 23.77% and 74.38%, respectively. Shares of Cellect Biotechnology, which focuses on developing solutions for immune system regeneration in Israel, have an RSI of 52.86. Register for free on and download the latest research report on APOP at:

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store